Skip to main content

Medical Drug Benefit Clinical Criteria Updates (Healthy Blue + MedicareSM HMO-DSNP)

Please note, this communication applies to Healthy Blue + MedicareSM (HMO D-SNP) offered by Blue Cross and Blue Shield of North Carolina (Blue Cross NC).

On May 20, 2022, the Pharmacy and Therapeutics (P&T) Committee approved the following Clinical Criteria applicable to the medical drug benefit for Blue Cross NC. These policies were developed, revised, or reviewed to support clinical coding edits.

Visit Clinical Criteria to search for specific policies. If you have questions or would like additional information, send an inquiry to druglist@ingenio-rx.com.

Please see the explanation/definition for each category of Clinical Criteria below:

• New: newly published criteria

• Revised: addition or removal of medical necessity requirements, new document number

• Updates marked with an asterisk (*) notate that the criteria may be perceived as more restrictive

Please share this notice with other members of your practice and office staff.

Note: The Clinical Criteria listed below applies only to the medical drug benefits contained within the member’s medical policy. This does not apply to pharmacy services. This notice is meant to inform the provider of new or revised criteria that has been adopted by Blue Cross NC only. It does not include details regarding any authorization requirements. Authorization rules are communicated via a separate notice.

Effective dateDocument numberClinical Criteria titleNew or revised
December 30 2022*ING-CC-0200AduhelmNew
December 30 2022*ING-CC-0215Ketamine injection (Ketalar)New
December 30 2022*ING-CC-0216Opdualag (nivolumab and relatlimab-rmbw)New
December 30 2022*ING-CC-0153Adakveo (crizanlizumab)Revised
December 30 2022*ING-CC-0002Colony Stimulating Factor AgentsRevised
December 30 2022*ING-CC-0124Keytruda (pembrolizumab)Revised
December 30 2022ING-CC-0101Torisel (temsirolimus)Revised
December 30 2022*ING-CC-0107Bevacizumab for Non-Ophthalmologic IndicationsRevised
December 30 2022ING-CC-0143Polivy (polatuzumab vedotin-piiq)Revised
December 30 2022*ING-CC-0092Adcetris (brentuximab vedotin)Revised
December 30 2022ING-CC-0106Erbitux (cetuximab)Revised
December 30 2022*ING-CC-0175Proleukin (aldesleukin)Revised
December 30 2022ING-CC-0116Bendamustine agentsRevised
December 30 2022*ING-CC-0145Libtayo (cemiplimab-rwlc)Revised
December 30 2022ING-CC-0151Yescarta (axicabtagene ciloleucel)Revised
December 30 2022*ING-CC-0032Botulinum ToxinRevised
December 30 2022*ING-CC-0052Dihydroergotamine (DHE) injectionRevised
December 30 2022*ING-CC-0068Growth HormoneRevised
December 30 2022*ING-CC-0087Gamifant (emapalumab)Revised
December 30 2022ING-CC-0194Cabenuva (cabotegravir extended-release; rilpivirine extended-release) InjectionRevised
December 30 2022ING-CC-0065Agents for Hemophilia A and von Willebrand DiseaseRevised
December 30 2022*ING-CC-0118Radioimmunotherapy and Somatostatin Receptor Targeted Radiotherapy (Azedra, Lutathera, Pluvicto, Zevalin)Revised
December 30 2022*ING-CC-0201Rybrevant (amivantamab-ymjw)Revised
December 30 2022*ING-CC-0119Yervoy (ipilimumab)Revised

For more information, visit Healthy Blue + Medicare.